Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BrainsWay Ltd. stock logo
BWAY
BrainsWay
$5.03
+2.0%
$5.76
$1.38
$7.61
$82.10M1.253,172 shs26,281 shs
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
$2.20
+2.8%
$2.18
$1.98
$4.48
$97.82M0.53120,189 shs80,946 shs
Liquidia Co. stock logo
LQDA
Liquidia
$12.55
-3.1%
$14.60
$5.71
$16.99
$984.56M0.16868,271 shs1.09 million shs
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$0.07
+18.2%
$0.08
$0.06
$1.25
$2.42M-0.0618,940 shs44,065 shs
Venus Concept Inc. stock logo
VERO
Venus Concept
$0.72
-5.3%
$0.82
$0.60
$4.70
$4.83M0.6627,119 shs10,084 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BrainsWay Ltd. stock logo
BWAY
BrainsWay
+1.93%-0.40%-7.37%-17.68%+224.52%
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
+2.80%+3.77%0.00%+3.77%-45.54%
Liquidia Co. stock logo
LQDA
Liquidia
-3.09%-9.45%-19.91%+4.85%+87.31%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
-9.72%-14.47%-26.09%-27.78%-91.85%
Venus Concept Inc. stock logo
VERO
Venus Concept
-10.69%-6.94%+0.13%-40.42%-75.97%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BrainsWay Ltd. stock logo
BWAY
BrainsWay
2.6202 of 5 stars
3.35.00.00.02.50.80.6
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
1.8896 of 5 stars
3.51.00.00.02.32.50.6
Liquidia Co. stock logo
LQDA
Liquidia
2.4246 of 5 stars
3.31.00.00.02.74.20.6
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
1.7748 of 5 stars
3.50.00.04.50.61.70.0
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BrainsWay Ltd. stock logo
BWAY
BrainsWay
2.67
Moderate Buy$7.0039.17% Upside
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
3.00
Buy$3.5059.09% Upside
Liquidia Co. stock logo
LQDA
Liquidia
2.60
Moderate Buy$21.0067.33% Upside
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3.00
Buy$2.503,746.15% Upside
Venus Concept Inc. stock logo
VERO
Venus Concept
2.00
HoldN/AN/A

Current Analyst Ratings

Latest KRMD, NMRD, VERO, BWAY, and LQDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
4/1/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
3/14/2024
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
3/14/2024
Liquidia Co. stock logo
LQDA
Liquidia
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $32.00
3/13/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
3/11/2024
BrainsWay Ltd. stock logo
BWAY
BrainsWay
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/21/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BrainsWay Ltd. stock logo
BWAY
BrainsWay
$31.78M2.63N/AN/A$2.50 per share2.01
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
$28.52M3.53N/AN/A$0.45 per share4.89
Liquidia Co. stock logo
LQDA
Liquidia
$17.49M54.56N/AN/A$0.73 per share17.19
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$80K32.78N/AN/A($0.41) per share-0.16
Venus Concept Inc. stock logo
VERO
Venus Concept
$76.35M0.06N/AN/A($2.43) per share-0.30

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-$4.20M-$0.13N/A62.88N/A-13.20%-10.05%-6.88%5/15/2024 (Estimated)
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
-$13.74M-$0.29N/AN/AN/A-48.18%-27.82%-21.30%5/1/2024 (Confirmed)
Liquidia Co. stock logo
LQDA
Liquidia
-$78.50M-$1.20N/AN/AN/A-448.89%-132.16%-65.35%5/2/2024 (Estimated)
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
-$14.14M-$0.39N/AN/AN/AN/A-142.69%N/A
Venus Concept Inc. stock logo
VERO
Venus Concept
-$37.25M-$6.85N/AN/AN/A-48.79%N/A-36.21%5/15/2024 (Confirmed)

Latest KRMD, NMRD, VERO, BWAY, and LQDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2024N/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/AN/A  
5/1/2024N/A
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
-$0.04N/A+$0.04N/AN/AN/A  
4/1/2024Q4 2023
Venus Concept Inc. stock logo
VERO
Venus Concept
N/A-$2.01-$2.01-$2.01N/A$18.13 million
3/13/2024Q4 2023
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
-$0.04-$0.02+$0.02$0.12$7.01 million$7.19 million
3/13/2024Q4 2023
Liquidia Co. stock logo
LQDA
Liquidia
-$0.23-$0.42-$0.19-$0.42$5.29 million$4.53 million
3/6/202412/31/2023
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-$0.03-$0.01+$0.02N/A$8.40 million$9.03 million    
2/12/2024Q3 2024
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/A-$0.12-$0.12-$0.17N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BrainsWay Ltd. stock logo
BWAY
BrainsWay
N/AN/AN/AN/AN/A
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
N/AN/AN/AN/AN/A
Liquidia Co. stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BrainsWay Ltd. stock logo
BWAY
BrainsWay
N/A
5.68
5.30
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
0.02
4.55
3.77
Liquidia Co. stock logo
LQDA
Liquidia
N/A
4.85
4.85
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/A
0.19
0.03
Venus Concept Inc. stock logo
VERO
Venus Concept
N/A
2.13
1.39

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BrainsWay Ltd. stock logo
BWAY
BrainsWay
30.11%
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
58.60%
Liquidia Co. stock logo
LQDA
Liquidia
64.54%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
4.41%
Venus Concept Inc. stock logo
VERO
Venus Concept
87.41%

Insider Ownership

CompanyInsider Ownership
BrainsWay Ltd. stock logo
BWAY
BrainsWay
19.00%
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
25.60%
Liquidia Co. stock logo
LQDA
Liquidia
31.60%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
41.60%
Venus Concept Inc. stock logo
VERO
Venus Concept
51.39%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BrainsWay Ltd. stock logo
BWAY
BrainsWay
13416.64 million13.48 millionNot Optionable
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
8245.71 million34.01 millionOptionable
Liquidia Co. stock logo
LQDA
Liquidia
14576.03 million52.00 millionOptionable
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3640.35 million23.57 millionOptionable
Venus Concept Inc. stock logo
VERO
Venus Concept
3046.36 million3.09 millionNot Optionable

KRMD, NMRD, VERO, BWAY, and LQDA Headlines

SourceHeadline
Venus Concept Announces Loan Purchase and Completion of First Phase of RefinancingVenus Concept Announces Loan Purchase and Completion of First Phase of Refinancing
finance.yahoo.com - April 24 at 7:48 PM
Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
globenewswire.com - April 15 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
finanznachrichten.de - April 9 at 1:29 AM
Venus Concept Announces Approval For Venus Bliss MAX In Israel - Quick FactsVenus Concept Announces Approval For Venus Bliss MAX In Israel - Quick Facts
markets.businessinsider.com - April 8 at 10:21 AM
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
globenewswire.com - April 8 at 7:30 AM
Ranking every single MoonSwatch thats ever droppedRanking every single MoonSwatch that's ever dropped
gq-magazine.co.uk - April 3 at 10:37 PM
On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?
news.yahoo.com - April 3 at 10:37 PM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
finance.yahoo.com - April 3 at 7:36 AM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
globenewswire.com - April 3 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - April 2 at 9:35 PM
VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023
investorplace.com - April 1 at 1:03 PM
Venus Concept: Q4 Earnings SnapshotVenus Concept: Q4 Earnings Snapshot
houstonchronicle.com - April 1 at 9:42 AM
Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
globenewswire.com - April 1 at 7:00 AM
Venus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
finanznachrichten.de - March 26 at 2:33 AM
Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
globenewswire.com - March 25 at 7:30 AM
Venus Concept Launches "NEXThetics" ProgramVenus Concept Launches "NEXThetics" Program
stockhouse.com - March 13 at 10:30 AM
Venus Concept Launches “NEXThetics” ProgramVenus Concept Launches “NEXThetics” Program
globenewswire.com - March 12 at 4:05 PM
Venus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 27 at 4:05 PM
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 23 at 8:00 AM
Nasdaq Surges 300 Points; NVIDIA Posts Strong ResultsNasdaq Surges 300 Points; NVIDIA Posts Strong Results
msn.com - February 23 at 1:09 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
finance.yahoo.com - February 22 at 10:08 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
globenewswire.com - February 22 at 7:30 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
finance.yahoo.com - February 20 at 10:42 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
globenewswire.com - February 20 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BrainsWay logo

BrainsWay

NASDAQ:BWAY
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
KORU Medical Systems logo

KORU Medical Systems

NASDAQ:KRMD
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
Liquidia logo

Liquidia

NASDAQ:LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Nemaura Medical logo

Nemaura Medical

NASDAQ:NMRD
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Venus Concept logo

Venus Concept

NASDAQ:VERO
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.